Description
MEXCORT-30 contains Deflazacort U.S.P. 6 mg/5 mL in an oral suspension formulation. Deflazacort is a corticosteroid that produces glucocorticoid effects and can help reduce inflammation and suppress excessive immune activity when prescribed for appropriate medical conditions.
For related corticosteroid formulations and other pharmaceutical products, explore the Medhexa Pharma product range for additional formulations and therapeutic segments.
Therapeutic Segment
Corticosteroid | Anti-inflammatory Therapy | Immunosuppressive Therapy | Oral Suspension
Uses of MEXCORT-30
Deflazacort is a prescription corticosteroid. Its approved indication varies by market and formulation. For example, current U.S. prescribing information for deflazacort oral suspension indicates its use for Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Depending on the approved indication and prescribing information applicable to the specific product, MEXCORT-30 may be prescribed as part of corticosteroid therapy to:
- Help reduce inflammation.
- Suppress excessive immune or inflammatory activity.
- Support corticosteroid treatment in conditions where deflazacort is clinically appropriate.
- Provide an oral suspension dosage form when prescribed by a healthcare professional.
Important: The exact indication for MEXCORT-30 should follow the product’s approved prescribing information and the treating healthcare professional’s recommendation.
Key Benefits of MEXCORT-30
- Contains Deflazacort U.S.P. 6 mg/5 mL in an oral suspension.
- Provides corticosteroid therapy in a liquid dosage form.
- Deflazacort acts through glucocorticoid receptors to produce anti-inflammatory and immunosuppressive effects.
- The suspension format can be useful when an oral liquid dosage form is clinically preferred.
- Comes in a convenient 30 ML WITH CAP & CARTON pack.
How MEXCORT-30 Works
Deflazacort is a corticosteroid prodrug. Its active metabolite acts through glucocorticoid receptors and produces anti-inflammatory and immunosuppressive effects. These actions influence inflammatory and immune pathways in the body.
Because corticosteroids affect several physiological processes, deflazacort should be used only for an appropriate medical indication and under professional supervision.
Common Side Effects of MEXCORT-30
Corticosteroid treatment can cause different adverse effects depending on the dose, duration of therapy and individual patient factors. Possible effects may include:
- Increased appetite
- Weight gain
- Stomach discomfort
- Mood changes
- Difficulty sleeping
- Increased blood glucose
- Increased blood pressure
- Increased susceptibility to infections
Longer-term corticosteroid treatment can also affect bone mineral density, growth, the eyes, adrenal function and other body systems.
Seek medical attention if serious or unusual symptoms develop during treatment.
Important Safety Information
MEXCORT-30 contains a corticosteroid and should be used strictly according to medical advice.
- Do not start, stop or change the dose without consulting a healthcare professional.
- Do not stop prolonged corticosteroid therapy abruptly. Treatment may need gradual dose reduction to reduce the risk of adrenal insufficiency.
- Deflazacort can suppress immune function and increase the risk of new or worsening infections. It can also mask some signs of infection.
- Long-term use can affect bone mineral density and may affect growth in pediatric patients.
- Corticosteroids may cause changes in blood glucose, blood pressure and fluid/electrolyte balance.
- Inform the healthcare professional about existing infections, diabetes, hypertension, gastrointestinal problems, eye conditions or other ongoing medical conditions.
- Tell your doctor about all prescription medicines, over-the-counter medicines, supplements and herbal products because deflazacort can interact with certain medicines, including CYP3A4 inhibitors and inducers.
- Discuss vaccination requirements with the healthcare professional before and during corticosteroid therapy. Live vaccines may require special consideration during immunosuppressive corticosteroid treatment.
- Keep the medicine out of reach of children.
For detailed safety and prescribing information, healthcare professionals can refer to the current Deflazacort Oral Suspension prescribing information.
Dosage & Administration
The dosage of MEXCORT-30 should be individualized according to the patient’s condition, age, body weight, clinical response and the indication for treatment.
Do not calculate the dose from the 30 ML bottle size.
For the U.S.-approved deflazacort oral suspension formulation, the current prescribing information gives a recommended dosage of approximately 0.9 mg/kg/day once daily for its approved indication, with gradual dose reduction recommended when treatment has continued for more than a few days. However, the concentration of that U.S. product differs from the 6 mg/5 mL strength supplied for MEXCORT-30. Therefore, the exact dose and volume for MEXCORT-30 must follow its approved product label and the prescribing healthcare professional’s instructions.
Administration: Shake the suspension well before use and measure the prescribed quantity with an appropriate measuring device. Do not use a household spoon for dosing.
Storage
- Store MEXCORT-30 according to the storage conditions stated on the product label.
- Keep the bottle tightly closed when not in use.
- Protect the suspension from excessive heat and moisture.
- Keep out of reach of children.
- Do not use after the expiry date.
- Follow the manufacturer’s instructions regarding use after opening.
